AGT‑115 is a re-engineered form of human erythropoietin (EPO) that ArmaGen is investigating for the treatment of Parkinson’s disease (PD) and stroke. EPO is a potent neuroprotective agent, however; it cannot cross the BBB in natural form. AGT-115, a neurotrophin fusion molecule, overcomes this obstacle by crossing the BBB via receptor-mediated transport.
In preclinical studies, AGT-m115 was rapidly transported across the BBB in a rhesus monkey model.1 Additionally, AGT-m115 reduced stroke volume and neural deficit by 98% in a rat model of stroke.2
Preclinical validation studies of AGT-115 are ongoing in PD and stroke.
1 Boado MJ, et al. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther. 2010;333:961-969
2 Fu A, et al. Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein. Brain Res. 2010;1360:193-197